Edition:
United States

Protalix Biotherapeutics Inc (PLX.A)

PLX.A on American Stock Exchange

0.59USD
21 Sep 2017
Change (% chg)

-- (--)
Prev Close
$0.59
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
95,514
52-wk High
$1.51
52-wk Low
$0.28

Chart for

About

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other... (more)

Overall

Beta: 0.21
Market Cap(Mil.): ₪260.96
Shares Outstanding(Mil.): 133.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Protalix Biotherapeutics qtrly loss per share from continuing operations $0.47 ​

* Protalix Biotherapeutics reports 2017 second quarter results and provides corporate update

Aug 09 2017

BRIEF-Protalix Biotherapeutics announces FDA approval to operate its current facility as a multi-product facility

* Protalix Biotherapeutics announces FDA approval to operate its current facility as a multi-product facility

Jun 01 2017

BRIEF-Protalix Biotherapeutics reports Q1 loss per share $0.07 excluding items

* Protalix Biotherapeutics reports 2017 first quarter results and provides corporate update

May 10 2017

BRIEF-Protalix announces FDA investigational new drug clearance commence once-monthly dosing study of pegunigalsidase

* Protalix announces FDA investigational new drug clearance to commence once-monthly dosing study of pegunigalsidase alfa (prx-102) for the treatment of fabry disease

May 09 2017

BRIEF-Protalix Biotherapeutics announces positive results from phase II clinical trial of Alidornase Alfa

* Protalix Biotherapeutics announces positive results from phase II clinical trial of Alidornase Alfa (air dnase) for the treatment of cystic fibrosis

Apr 12 2017

Earnings vs. Estimates